Compare KraneShares Electric Vehicles and Future Mobility (KARS) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KraneShares Electric Vehicles and Future Mobility vs Spyre Therapeutics Inc. Common Stock — how do they compare? KraneShares Electric Vehicles and Future Mobility trades at $26.6 (market cap $70.90M), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.35B). The key difference: Spyre Therapeutics Inc. Common Stock is far larger — about 103.7× KraneShares Electric Vehicles and Future Mobility's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, KraneShares Electric Vehicles and Future Mobility nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold KraneShares Electric Vehicles and Future Mobility for 48 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| KARS | SYRE | |
|---|---|---|
Market Cap | $70.90M | $7.35B |
Volume | 2,312 | 1,624,631 |
Sector | Sector/Thematic | Health |
52-Week High | $38.01 | $108.92 |
52-Week Low | $26.72 | $22.18 |
Typical Hold Time | 48 Days | 0 Days |
Enterprise Value | — | $6.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KARS stock trades at $27.18, down 0.88% on the day with a bearish technical signal. The stock faces resistance at $29 and support at $28, with moving averages indicating selling pressure while oscillators remain neutral. Recent news highlights challenges in the US electric vehicle market, which may impact automotive sector performance.
The outlook remains cautious given technical weakness and sector headwinds. Investment opportunity depends on company-specific fundamentals currently unavailable, while risks include EV market softness and regulatory uncertainty surrounding Chinese competition in the automotive industry.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About KraneShares Electric Vehicles and Future Mobility
KARS invests in the global electric vehicle ecosystem and future mobility. It tracks the Bloomberg Electric Vehicles Index, providing exposure to EV manufacturers, battery technology, and lithium miners like Tesla, BYD, and Albemarle.
Read more on KARS →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
